Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report

Leukemia. 2013 Jan;27(1):238-41. doi: 10.1038/leu.2012.168. Epub 2012 Jun 22.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cytarabine / administration & dosage
  • DNA (Cytosine-5-)-Methyltransferases / genetics*
  • DNA Methyltransferase 3A
  • Daunorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Exons / genetics*
  • Female
  • Follow-Up Studies
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / mortality*
  • Male
  • Middle Aged
  • Mitoxantrone / administration & dosage
  • Mutation / genetics*
  • Neoplasm Staging
  • Prognosis
  • Survival Rate

Substances

  • DNMT3A protein, human
  • Cytarabine
  • Etoposide
  • Mitoxantrone
  • DNA (Cytosine-5-)-Methyltransferases
  • DNA Methyltransferase 3A
  • Daunorubicin